Repligen CORP 8-K filings

Repligen Corporation announced robust second quarter 2026 financial results, with revenue up 12% year-over-year, and raised its full-year financial guidance.

Repligen Corporation announced its definitive agreement to acquire BioLife Solutions, Inc. for approximately $1.5 billion, aiming to expand its cell therapy capabilities.

Repligen Corporation announced the results of its 2026 Annual Meeting of Stockholders, where all director nominees were elected and key proposals were approved.

Repligen Corporation announced robust first-quarter 2026 financial results, with a 15% year-over-year revenue increase and raised full-year adjusted EPS guidance.

Repligen Corporation reported strong fourth quarter and full year 2025 financial results, surpassing guidance, and provided optimistic 2026 financial projections with expected margin expansion.

Repligen Corporation announced the election of Dr. Martin D. Madaus as Chair of the Board, succeeding Tony J. Hunt upon his previously announced retirement.

Repligen Corporation reported robust third-quarter 2025 financial results with a 22% revenue increase and raised its full-year financial guidance, driven by broad-based organic growth across all franchises and geographies.

Repligen Corporation announced the appointment of Violetta Hughes as its new Chief Accounting Officer, effective September 1, 2025, to enhance financial reporting and SOX compliance.

Repligen Corporation announced robust second-quarter 2025 financial results, driven by broad-based growth across its bioprocessing portfolio, leading to an upward revision of its full-year revenue guidance.

Repligen Corporation's stockholders approved an amendment to the company's Certificate of Incorporation to limit the liability of certain officers, as permitted by Delaware law, during the 2025 Annual Meeting of Shareholders.

Repligen Corporation announced a 10% increase in total revenue and a 14% increase in organic non-COVID revenue for the first quarter of 2025, along with an updated full-year financial guidance.

Repligen Corporation announces its Q4 and full-year 2024 financial results, showing slight revenue increases and providing a positive outlook for 2025 with projected growth.

Repligen Corporation announced a 10% year-over-year revenue increase for the third quarter of 2024, driven by strong performance in CDMO and new modalities, and narrowed its full-year revenue guidance.

Repligen Corporation will restate its financial statements for 2023 and the first half of 2024 due to an error in recognizing a $17.3 million cancellation payment, though the company reaffirms its full-year 2024 revenue guidance.

Repligen Corporation announced its second quarter 2024 financial results, reporting $154 million in revenue and narrowing its full-year revenue guidance while maintaining adjusted EPS guidance.

Repligen Corporation reported an unauthorized third party accessed certain files on its information systems, prompting an immediate investigation and remediation effort.

Repligen Corporation has appointed Olivier Loeillot as CEO, succeeding Tony J. Hunt, who will become Executive Chair, effective September 1, 2024.

Repligen Corporation has announced a planned leadership transition, with Tony J. Hunt moving to Executive Chair and Olivier Loeillot becoming the new CEO, effective September 1, 2024.

Repligen Corporation successfully held its 2024 Annual Meeting, electing all nominated directors and ratifying Ernst & Young LLP as its independent auditor.

Repligen Corporation announced its first quarter 2024 financial results, reporting $151 million in revenue and reaffirming its full-year financial guidance.

Repligen Corporation has appointed life sciences executive Maggie A. Pax to its Board of Directors, increasing the board size to nine members.

Repligen Corporation announced its fourth quarter and full year 2023 financial results, showing a decrease in revenue compared to 2022, but with positive momentum in new modalities and a strong book-to-bill ratio.